AccuTheranostics, Inc.

AccuTheranostics, Inc. is a biotechnology startup founded in 2012 with a mission to revolutionize personalized chemotherapy for cancer patients. Their slogan, "Elevating personalized chemotherapy for cancer patients with advanced, patient-specific diagnostics and prognostics," encapsulates their key focus. The company specializes in providing tailored treatment through a range of laboratory tests. Their flagship service, ChemoFit™, is an innovative lab test that uses a patient’s own tumor cells to identify the most effective chemotherapy drugs. This personalized approach allows physicians to select treatments with the highest potential while avoiding those to which the patient’s tumor is resistant. The last investment, a Convertible Note, was secured on 01 January 2017 from Launch NY. AccuTheranostics' disruptive approach to cancer treatment and its focus on individualized care makes it a promising player in the biotechnology industry.